US 12,239,615 B2
Hydroxynorketamine for the use in the treatment of depression
Helene Rey, Pratteln (CH)
Assigned to Ketabon GmbH, Munich (DE)
Filed by KETABON GMBH, Munich (DE)
Filed on Jun. 21, 2023, as Appl. No. 18/212,375.
Application 18/212,375 is a continuation of application No. 16/625,845, granted, now 11,723,883, previously published as PCT/EP2018/066823, filed on Jun. 22, 2018.
Claims priority of application No. 17177660 (EP), filed on Jun. 23, 2017.
Prior Publication US 2023/0330043 A1, Oct. 19, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/135 (2006.01); A61K 9/28 (2006.01)
CPC A61K 31/135 (2013.01) [A61K 9/2866 (2013.01)] 18 Claims
 
1. A modified release dosage form for use in a method for the treatment of depression, to be orally administered, wherein the modified release dosage form is a prolonged-release dosage form comprising at least one prodrug of hydroxynorketamine wherein said prodrug is ketamine or pharmaceutically acceptable salts or solvates or mixtures thereof, wherein the oral administration of the prolonged-release dosage from results in plasma concentration profiles exhibiting a ratio of AUCK/HNK between 1:7 and 1:25.